Clinical Trial Update: A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM) [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluating allogeneic CMV-specific cytotoxic T cells for glioblastoma multiforme has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Allogeneic CMV-specific T cells (CMV-specific cytotoxic T cells)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Glioblastoma Multiforme | Phase 1 | Status: TERMINATED